{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Edoxaban+30+mg", "query": { "intervention": "Edoxaban 30 mg" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 12, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Edoxaban+30+mg&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-09T01:52:11.700Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02567461", "title": "Edoxaban in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Coronary Artery Disease" ], "interventions": [ { "name": "Edoxaban 60 mg", "type": "DRUG" }, { "name": "Edoxaban 30 mg", "type": "DRUG" }, { "name": "Clopidogrel 75 mg", "type": "DRUG" }, { "name": "Aspirin 81 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2016-03", "completion_date": "2018-03-15", "has_results": false, "last_update_posted_date": "2018-04-06", "last_synced_at": "2026-09-09T01:52:11.700Z", "location_count": 1, "location_summary": "Jacksonville, Florida", "locations": [ { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02567461" }, { "nct_id": "NCT02072434", "title": "Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atrial Fibrillation" ], "interventions": [ { "name": "Edoxaban", "type": "DRUG" }, { "name": "Warfarin", "type": "DRUG" }, { "name": "Enoxaparin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2199, "start_date": "2014-03-25", "completion_date": "2016-02-03", "has_results": true, "last_update_posted_date": "2019-03-15", "last_synced_at": "2026-09-09T01:52:11.700Z", "location_count": 28, "location_summary": "Phoenix, Arizona • Escondido, California • Newport Beach, California + 25 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Escondido", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02072434" }, { "nct_id": "NCT02798471", "title": "Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Venous Thromboembolism (VTE)", "Pulmonary Embolism", "Deep Vein Thrombosis (DVT)" ], "interventions": [ { "name": "Edoxaban", "type": "DRUG" }, { "name": "Standard of Care", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Day", "maximum_age": "17 Years", "sex": "ALL", "summary": "1 Day to 17 Years" }, "enrollment_count": 290, "start_date": "2017-03-27", "completion_date": "2022-05-24", "has_results": true, "last_update_posted_date": "2025-02-28", "last_synced_at": "2026-09-09T01:52:11.700Z", "location_count": 22, "location_summary": "Tucson, Arizona • Los Angeles, California • Stanford, California + 16 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02798471" }, { "nct_id": "NCT03395639", "title": "Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cardiac Disease" ], "interventions": [ { "name": "Edoxaban", "type": "DRUG" }, { "name": "Standard of Care (SOC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Day", "maximum_age": "17 Years", "sex": "ALL", "summary": "1 Day to 17 Years" }, "enrollment_count": 168, "start_date": "2018-05-15", "completion_date": "2021-12-03", "has_results": true, "last_update_posted_date": "2022-07-26", "last_synced_at": "2026-09-09T01:52:11.700Z", "location_count": 14, "location_summary": "Birmingham, Alabama • Mesa, Arizona • Los Angeles, California + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03395639" }, { "nct_id": "NCT02073682", "title": "Cancer Venous Thromboembolism (VTE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Venous Thromboembolism (VTE)", "Deep Vein Thrombosis (DVT)", "Pulmonary Embolism (PE)", "Cancer" ], "interventions": [ { "name": "Edoxaban", "type": "DRUG" }, { "name": "Dalteparin", "type": "DRUG" }, { "name": "Low molecular weight heparin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1046, "start_date": "2015-07-16", "completion_date": "2017-09-15", "has_results": true, "last_update_posted_date": "2019-03-06", "last_synced_at": "2026-09-09T01:52:11.700Z", "location_count": 4, "location_summary": "Brandon, Florida • Jonesboro, Georgia • Detroit, Michigan + 1 more", "locations": [ { "city": "Brandon", "state": "Florida" }, { "city": "Jonesboro", "state": "Georgia" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Norfolk", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02073682" }, { "nct_id": "NCT03968393", "title": "Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Stroke", "Atrial Fibrillation" ], "interventions": [ { "name": "Non-vitamin K oral anticoagulant (NOAC)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Population Health Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": null, "sex": "ALL", "summary": "55 Years and older" }, "enrollment_count": 2270, "start_date": "2019-06-14", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-01-12", "last_synced_at": "2026-09-09T01:52:11.700Z", "location_count": 2, "location_summary": "Los Angeles, California • Houston, Texas", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03968393" }, { "nct_id": "NCT01802775", "title": "Edoxaban in Peripheral Arterial Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Peripheral Arterial Disease" ], "interventions": [ { "name": "edoxaban", "type": "DRUG" }, { "name": "Clopidogrel", "type": "DRUG" }, { "name": "Aspirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 203, "start_date": "2013-02-06", "completion_date": "2014-12-03", "has_results": true, "last_update_posted_date": "2019-02-26", "last_synced_at": "2026-09-09T01:52:11.700Z", "location_count": 26, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 23 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01802775" }, { "nct_id": "NCT02943785", "title": "Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atrial Fibrillation" ], "interventions": [ { "name": "Edoxaban-based Regimen", "type": "DRUG" }, { "name": "VKA-based Regimen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1426, "start_date": "2017-03-21", "completion_date": "2021-02-28", "has_results": true, "last_update_posted_date": "2022-03-24", "last_synced_at": "2026-09-09T01:52:11.700Z", "location_count": 66, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 60 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02943785" }, { "nct_id": "NCT03950076", "title": "EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Intracranial Hemorrhages", "Atrial Fibrillation" ], "interventions": [ { "name": "Edoxaban", "type": "DRUG" }, { "name": "Non-anticoagulant medical therapy", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Population Health Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "45 Years", "maximum_age": null, "sex": "ALL", "summary": "45 Years and older" }, "enrollment_count": 948, "start_date": "2019-09-20", "completion_date": "2026-07-22", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-09-09T01:52:11.700Z", "location_count": 10, "location_summary": "Elk Grove Village, Illinois • Lisle, Illinois • New Orleans, Louisiana + 7 more", "locations": [ { "city": "Elk Grove Village", "state": "Illinois" }, { "city": "Lisle", "state": "Illinois" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Queens", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03950076" }, { "nct_id": "NCT02206100", "title": "PK and PD of Single, Escalating Doses of PER977 Following Enoxaparin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "PER977", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "enoxaparin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 40, "start_date": "2014-04", "completion_date": "2014-08", "has_results": false, "last_update_posted_date": "2020-05-21", "last_synced_at": "2026-09-09T01:52:11.700Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02206100" } ] }